Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Noel Barrett

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Vaccine|November 9, 2010
Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humansBrian A Crowe, Peter Brühl, Marijan Gerencer, et al.
Virology Journal|April 18, 2014
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceChristine Hohenadl, Walter Wodal, Astrid Kerschbaum, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trialNina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, et al.
Journal of Virology|December 15, 2015
Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus VaccinesYvonne Beck, Richard Fritz, Klaus Orlinger, et al.
Transfusion|October 11, 2011
Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenzaThomas R Kreil, John K Mc Vey, Laura Shau-Ping Lei, et al.
Human Vaccines & Immunotherapeutics|July 17, 2013
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesLarry R Smith, Walter Wodal, Brian A Crowe, et al.
Vaccine|April 12, 2011
Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protectionGeorg W Holzer, Sogue Coulibaly, Gerald Aichinger, et al.
Vaccine|May 4, 2010
Comparison of immunogenicity and safety between two paediatric TBE vaccinesEva Maria Pöllabauer, Borislava G Pavlova, Alexandra Löw-Baselli, et al.
Plos One|February 2, 2011
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunityAnnett Hessel, Michael Schwendinger, Georg W Holzer, et al.
Vaccine|August 1, 2012
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memoryAlexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Vaccine|November 9, 2010
Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humansBrian A Crowe, Peter Brühl, Marijan Gerencer, et al.
Virology Journal|April 18, 2014
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceChristine Hohenadl, Walter Wodal, Astrid Kerschbaum, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trialNina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, et al.
Journal of Virology|December 15, 2015
Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus VaccinesYvonne Beck, Richard Fritz, Klaus Orlinger, et al.
Transfusion|October 11, 2011
Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenzaThomas R Kreil, John K Mc Vey, Laura Shau-Ping Lei, et al.
Human Vaccines & Immunotherapeutics|July 17, 2013
Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesLarry R Smith, Walter Wodal, Brian A Crowe, et al.
Vaccine|April 12, 2011
Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protectionGeorg W Holzer, Sogue Coulibaly, Gerald Aichinger, et al.
Vaccine|May 4, 2010
Comparison of immunogenicity and safety between two paediatric TBE vaccinesEva Maria Pöllabauer, Borislava G Pavlova, Alexandra Löw-Baselli, et al.
Plos One|February 2, 2011
Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunityAnnett Hessel, Michael Schwendinger, Georg W Holzer, et al.
Vaccine|August 1, 2012
A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memoryAlexandra Loew-Baselli, Borislava G Pavlova, Sandor Fritsch, et al.
Pageof 7